BioNTech SE and DualityBiologics have announced the topline results of their global Phase 3 clinical trial, DYNASTY-Breast02, which evaluates trastuzumab pamirtecan in patients with HR+/HER2-low metastatic breast cancer. The trial met its primary endpoint, demonstrating a statistically significant but modest improvement in progression-free survival (PFS) when compared to the investigator’s choice of chemotherapy for chemotherapy-naïve patients who have progressed on endocrine therapy. This development is significant as it showcases BioNTech's ongoing commitment to advancing cancer treatments.
BioNTech SE, incorporated in Germany, operates under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). The company trades on the Nasdaq under the ticker BNTX. BioNTech is recognized for its pioneering work in developing innovative therapies for cancer and other serious diseases, with a strong focus on next-generation biopharmaceuticals.
The SEC filing dated October 26, 2026, reveals that the DYNASTY-Breast02 trial has shown a modest improvement in PFS, although the overall survival data remains immature at this interim analysis. The trial reported a higher rate of interstitial lung disease (ILD) compared to previous studies, with most cases classified as Grade 1 and 2. Despite this, the overall safety profile was consistent with earlier trials, and no new safety signals were detected.
The topline results indicate that while trastuzumab pamirtecan may offer some benefit, its potential impact on the treatment landscape for HR+/HER2-low metastatic breast cancer may be limited. The companies plan to discuss the findings further to determine the next steps in their development strategy.
BioNTech and DualityBio are currently conducting three ongoing clinical trials involving trastuzumab pamirtecan, including two global Phase 3 trials targeting HR+/HER2-low metastatic breast cancer and HER2-expressing recurrent endometrial cancer, as well as a Phase 1/2 trial for patients with advanced or metastatic solid tumors.
As the biopharmaceutical industry continues to evolve, the results from this trial could influence treatment protocols and patient options in the competitive oncology market. With major players like Bristol Myers Squibb and Genentech also engaged in this space, the findings may prompt further research and development efforts aimed at improving patient outcomes.
The filing does not specify what happens next, but the companies are expected to analyze the data further and consult with regulatory authorities regarding the implications of these results.